<SEC-DOCUMENT>0001829126-24-004389.txt : 20240726
<SEC-HEADER>0001829126-24-004389.hdr.sgml : 20240726
<ACCEPTANCE-DATETIME>20240624133040
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001829126-24-004389
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240624

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nexalin Technology, Inc.
		CENTRAL INDEX KEY:			0001527352
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				275566468
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1776 YORKTOWN
		STREET 2:		SUITE 550
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77056
		BUSINESS PHONE:		(832) 260-0222

	MAIL ADDRESS:	
		STREET 1:		1776 YORKTOWN
		STREET 2:		SUITE 550
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77056
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 3pt"><B>WARSHAW BURSTEIN, LLP</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 3pt">575 Lexington Avenue</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 3pt">New York, NY 10022</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 3pt">Telephone: 212-984-7700</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 3pt"><U>www.wbny.com</U> </P> </TD>
    <TD STYLE="vertical-align: top; width: 50%; text-align: right"><IMG SRC="corresp_001.jpg" ALT="" STYLE="height: 120px; width: 120px"></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">June&nbsp;24, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B><U>VIA EDGAR</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">United States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Office of Industrial Applications and Services</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Washington, D.C. 20549</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.75in">Attention: </TD>
    <TD> Mr. Robert Augustin</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Ms. Jane Park</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><B>Re:</B>
    <TD><B>Nexalin Technology, Inc.</B></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><B>Amendment No. 1 to Registration Statement on Form S-1</B></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><B>Filed June&nbsp;14, 2024</B></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><B>File No. 333-279684</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">On behalf of our client, Nexalin Technology, Inc., a Delaware corporation (the &ldquo;<B><U>Company</U></B>&rdquo;), we are writing to submit the Company&rsquo;s response to the comment of the staff (the &ldquo;<B><U>Staff</U></B>&rdquo;) of the Division of Corporation Finance of the United States Securities and Exchange Commission (the &ldquo;<B><U>SEC</U></B>&rdquo;) with respect to the above-referenced Registration Statement on Form S-1 filed on June&nbsp;14, 2024 (File No. 333-279684, the &ldquo;<B><U>Registration Statement</U></B>&rdquo;), contained in the Staff&rsquo;s letter dated June&nbsp;21, 2024 (the &ldquo;<B><U>Comment Letter</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">For ease of reference, the comment contained in the Comment Letter is printed below in bold and is followed by the Company&rsquo;s response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><U>Amendment No. 1 to Registration Statement on Form S-1 filed June&nbsp;14, 2024</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><U>General</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">1.</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>We note your response to our prior comment 1. Please revise to address the following comments:</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>We note your revised disclosure that you &ldquo;expect a portion of [y]our revenues will be derived from China through the Joint Venture.&rdquo; Please revise to expand your disclosure relating to your Joint-Venture related revenue, including the proportion of your revenue that was derived through your Joint Venture during the 2023 fiscal year and the quarterly period ended March&nbsp;31, 2024.</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>WARSHAW BURSTEIN, LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B>United States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Division of Corporation Finance - Office of Industrial Applications and Services</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">June&nbsp;24, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Page&nbsp;2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><U>Response</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">During the 2023 fiscal year, the
Company sold equipment to the Joint Venture, resulting in revenue to the Company in the amount of $3,614 (accounting for 3.3% of the
Company&rsquo;s revenues in such year). In the first fiscal quarter of 2024, the Company recognized $5,783 in pass-through other
income from the Joint Venture included in &ldquo;Other Income&rdquo;, as disclosed in the Company&rsquo;s Report on Form 10-Q for
the quarter ended March 31. 2024. As stated in such Form 10-Q, the Company recognizes its investment in the Joint Venture as an
asset at cost and measures its investment by recognizing the Company&rsquo;s share of earnings or losses of the Joint Venture on a
one-quarter reporting lag. As noted in our June 14, 2024 response to the Staff&rsquo;s comment letter dated June 5, 2024, the Company
received no revenue from operations from China during the first quarter of 2024. As China continues to emerge from restrictions
related to the Covid-19 pandemic, the Company expects the Joint Venture to begin generating revenue in fiscal year 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><B>We note your statement in your response that 70.5% of the company&rsquo;s revenue was derived from sales in Oman and 29.5% of the quarterly revenue came from U.S. sales during the first fiscal quarter of 2024. We also refer to your disclosure on page 8 that The Sultanate of Oman&rsquo;s Ministry of Health granted the approval for the distribution of your Gen-2 device in March&nbsp;2024 and that you commenced sales of your device in Oman in the first quarter of 2024. Please revise to specify when you obtained approval for distribution of your Gen-2 device in March&nbsp;2024 and when you commenced sales of your device in Oman.</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"><U>Response</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">Oman&rsquo;s Ministry of Health
granted conditional approval for use of the Company&rsquo;s second generation (Gen-2) device on June 16, 2022, effective upon the
end user of our device opening and operating a mental health care clinic being constructed in Oman. The Company&rsquo;s first
shipment of a device to Oman was made on January 30, 2024 and received in Oman on February 5, 2024, in connection with the opening
of the end user&rsquo;s clinic, rendering the approval effective. Two additional devices were shipped to Oman on February 29, 2024 and were received by the end user
on March 6, 2024. Upon receipt of the two additional devices, the end user&rsquo;s clinic was operational, and the use of the device
to treat patients commenced pursuant to the approval. In total, the Company&rsquo;s sales in Oman totaled $55,500 in the first
quarter of 2024 (constituting 70.5% of the Company&rsquo;s revenue in such quarter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">Please do not hesitate to contact Martin Siegel, of Warshaw Burstein, LLP, at (212) 984-7741 with any questions or comments regarding this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 50%">Best regards,</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">/s/ Warshaw Burstein, LLP</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in; text-align: left">cc:</TD>
    <TD STYLE="text-align: justify">Nexalin Technology, Inc.</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Mark White, President and Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>corresp_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 corresp_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "W +<# 2(  A$! Q$!_\0
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M\)-0659$)ER PQ7(^'=,DUK7+2R0;EE8%QZ =37?S:]<^(/A=?75U'%&RR8
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MT29+..YWC&V3I6-8_% I=)#<:3;I!*1&[1##*#[UIZAHDOB3P%HMM97=LDD
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/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
